D. Western Therapeutics Institute, Inc. (TYO:4576)
88.00
0.00 (0.00%)
Aug 27, 2026, 2:38 PM JST
TYO:4576 Revenue
D. Western Therapeutics Institute had revenue of 17.89M JPY in the quarter ending June 30, 2026, a decrease of -76.54%. This brings the company's revenue in the last twelve months to 247.00M, down -41.33% year-over-year. In the year 2025, D. Western Therapeutics Institute had annual revenue of 387.00M, down -17.83%.
Revenue (ttm)
247.00M
Revenue Growth
-41.33%
P/S Ratio
20.50
Revenue / Employee
13.00M
Employees
19
Market Cap
5.06B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 387.00M | -84.00M | -17.83% |
| Dec 31, 2024 | 471.00M | 43.00M | 10.05% |
| Dec 31, 2023 | 428.00M | -20.00M | -4.46% |
| Dec 31, 2022 | 448.00M | 34.00M | 8.21% |
| Dec 31, 2021 | 414.00M | 59.00M | 16.62% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Transgenic Group | 13.64B |
| Kohjin Bio | 4.69B |
| Soiken Holdings | 3.87B |
| PRISM BioLab Co.,LTD | 737.27M |
| Chiome Bioscience | 615.15M |
| Cyfuse Biomedical K.K. | 305.00M |
| Ribomic | 7.50M |
| Noile-Immune Biotech | 1.00M |